DoJ probes AtriCure for improperly marketing for a-fib patients

DoJ is investigating whether AtriCure instructed hospitals to bill Medicare for surgical ablation using incorrect billing codes. Image Source: AtriCure

The U.S. Department of Justice (DoJ) has notified AtriCure has that it is conducting an investigation for potential False Claims Act and common law violations relating to AtriCure’s surgical ablation devices.

In a letter dated Oct. 27, the DoJ said it is investigating AtriCure’s marketing practices utilized in connection with its surgical ablation system to treat atrial fibrillation, a specific use outside the FDA’s 510(k) clearance, according to the West Chester, Ohio-based company.

The letter also states that the DoJ is investigating whether AtriCure instructed hospitals to bill Medicare for surgical ablation using incorrect billing codes.

AtriCure said it understands that the DoJ is in the process of compiling a document request. The company said it intends to cooperate with the DoJ in its investigation and operate its business in the ordinary course during the investigation.